Tagrisso

is used to treat lung cancer. Osimertinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

Tagrisso

Searching where to buy brand original Tagrisso 80 mg (osimertinib)? Order  right now in MTO Pharma online pharmacy. Click here to redirect to the product page.

Image result for viber whatsapp pngFor instant requiry and answers to your question contact us on Viber +380507552484 or on WhatsApp +380687225383

Carcinogenicity studies have not been performed with osimertinib. Osimertinib did not cause genetic damage in in vitro and in vivo assays.

Based on studies in animals, male fertility may be impaired by treatment with osimertinib. Degenerative changes were present in the testes in rats and dogs exposed to Tagrisso (osimertinib) for 1 month or more with evidence of reversibility in the rat. Following administration of osimertinib to rats for approximately 10 weeks at a dose of 40 mg/kg, at exposures 0.5-times the AUC observed in patients at the recommended dose of 80 mg, there was a reduction in male fertility, demonstrated by increased pre-implantation loss in
untreated females mated to treated males.

Nonclinical female fertility studies have not been conducted. In repeat dose toxicity studies, histological evidence of anestrus, corpora lutea degeneration in the ovaries and epithelial thinning in the uterus and vagina were seen in rats exposed to osimertinib for 1 month or more at exposures 0.3-times the AUC observed in patients at the recommended dose of 80 mg. Findings in the ovaries seen following 1 month of dosing exhibited evidence of reversibility.

Searching where to buy brand original Tagrisso 80 mg (osimertinib)? Order it right now in MTO Pharma online pharmacy. Click here to redirect to the product page.

Image result for viber whatsapp pngFor instant requiry and answers to your question contact us on Viber +380507552484 or on WhatsApp +380687225383

Categories: News

Leave a Reply

Your email address will not be published. Required fields are marked *